

# Imaging the Lipid-Phase-Dependent Pore Formation of Equinatoxin II in Droplet Interface Bilayers

N. Rojko,<sup>†</sup> B. Cronin,<sup>‡</sup> J. S. H. Daniai,<sup>‡</sup> M. A. B. Baker,<sup>‡</sup> G. Anderluh,<sup>†S\*</sup> and M. I. Wallace<sup>†\*</sup>

<sup>†</sup>Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia; <sup>‡</sup>Department of Chemistry, Oxford University, Oxford, UK; and <sup>S</sup>National Institute of Chemistry, Ljubljana, Slovenia

**ABSTRACT** Using phase-separated droplet interface bilayers, we observe membrane binding and pore formation of a eukaryotic cytotoxin, Equinatoxin II (EqII). EqII activity is known to depend on the presence of sphingomyelin in the target membrane and is enhanced by lipid phase separation. By imaging the ionic flux through individual pores *in vitro*, we observe that EqII pores form predominantly within the liquid-disordered phase. We observe preferential binding of labeled EqII at liquid-ordered/liquid-disordered domain boundaries before it accumulates in the liquid-disordered phase.

## INTRODUCTION

Pore-forming proteins such as Equinatoxin II (EqII) play a key role in all kingdoms of life. In bacteria they are important virulence factors (1,2), whereas in mammals they typically play the opposite role and are involved in host immune response (3,4). In general, pore-forming proteins undergo large conformational changes after binding to the target membrane, transitioning from a water-soluble monomer to an inserted multimeric pore with the potential to kill the target cell (2,5). This pore-formation mechanism is often facilitated by a specific, high-affinity receptor such as a transmembrane protein, lipid anchored protein, lipid, or lipid cluster.

EqII is a member of actinoporin protein family (6–8). In contrast to the more widely studied  $\beta$ -barrel pore-forming toxins, actinoporins insert  $\alpha$ -helices to permeabilize target cell membranes. Isolated from the sea anemone *Actinia equina*, EqII is believed to play a role in paralyzing prey and defending against predators (6,9). EqII is a ~20 kDa protein with high affinity for sphingomyelin (SM)-containing lipid membranes (10,11). EqII and other actinoporins bind to the lipid membrane through a cluster of exposed aromatic residues and a nearby phosphocholine-binding site (10,12,13). The key step in EqII pore formation is the conformational change that transfers the N-terminal  $\alpha$ -helix across the membrane (12,14). The current model for the EqII pore is one in which a single pore is formed from three or four monomers (15). Given this small number of contributing monomers but broad distribution of pore conductance (7), it is likely that the pore walls constitute not only  $\alpha$ -helices but also a torus of lipids (16). However, recent crystallographic data on the EqII homolog fragaceatoxin C disagree with this model and suggest a nonameric pore for actinoporins, which would not include membrane lipids (17).

EqII was previously reported to bind preferentially to domain boundaries in liquid-ordered/liquid-disordered

( $L_o/L_d$ ) phase coexisting lipid mixtures in both lipid monolayers (18) and giant unilamellar vesicles (GUVs) (19). *In vivo* studies also showed that EqII association with the plasma membrane leads to reorganization of the membrane and formation of microscopic domains, where the toxin preferentially colocalizes with raft proteins (20). In addition, although pore formation by EqII requires SM (21), SM itself is not sufficient for the N-terminal  $\alpha$ -helix conformational change that leads to pore formation (22); another factor is also required. These results led to the suggestion that the presence of lipid domains might play an important role in the pore-formation mechanism, and that EqII acts not only to form pores but also to remodel the membrane (19).

Here, we investigated the role of  $L_o/L_d$  phase separation on EqII pore formation using droplet interface bilayers (DIBs) (23,24). DIBs are made by contacting nanoliter aqueous droplets in an oil solution in the presence of phospholipids. Lipid monolayers form at each oil/water interface and when two such monolayers touch, a bilayer is created. DIBs can be used to simplify single-molecule fluorescence imaging of a lipid bilayer while retaining gigaohm seals of the membrane (25,26). Using total internal reflection fluorescence (TIRF) microscopy of phase-separated DIBs, we observed that EqII distributed predominantly into the  $L_d$  phase, and that pores also formed within this phase. We confirmed previous work showing that EqII localizes at the  $L_o/L_d$  phase boundary, and then examined the time dependence of this phenomenon. We observed preferential accumulation of EqII in the  $L_d$  phase over the  $L_o$  phase. These observations support previous measurements on lipid monolayers (18) and conflict with those obtained in GUVs (19). One must always take care when extrapolating results from *in vitro* experiments to the *in vivo* action of EqII. For example, Sezgin and co-workers (27) recently showed that the partitioning of raft proteins is dependent on the preparation method in phase-separated giant plasma membrane vesicles. It is therefore possible that beyond simple demixing, the relative degree of ordering between phases present in

Submitted April 4, 2013, and accepted for publication November 27, 2013.

\*Correspondence: mark.wallace@chem.ox.ac.uk or gregor.anderluh@ki.si

Editor: Claudia Steinem.

© 2014 by the Biophysical Society  
0006-3495/14/04/1630/8 \$2.00

<http://dx.doi.org/10.1016/j.bpj.2013.11.4507>



these experiments may affect the binding of EqtlI to the membrane and hence affect the mechanistic outcome. Such differences might help explain the differences between these observations and those made previously in GUVs.

## MATERIALS AND METHODS

### Materials

All materials were obtained from Sigma-Aldrich unless otherwise specified, and used without further purification. All buffers were filtered before use (0.2  $\mu\text{m}$  cellulose acetate; Nalgene) and buffers used to make DIBs were treated with Chelex 100 ion exchange resin (biotechnology grade, 100–200 mesh; BioRad). 1,2-Diphytanoyl-*sn*-glycero-3-phosphocholine (DPhPC), egg SM (eSM; egg, chicken), and cholesterol (Chol; ovine wool) were obtained from Avanti Polar Lipids, and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI<sub>18</sub> (3); DiI), 3,3'-dilinoleoyloxacarboxyanine perchlorate (FAST DiO; DiOC<sub>18</sub> (2)), and *N*-(6-tetramethylrhodaminethiocarbonyl) 1,2-dihexadecanoyl-*sn*-glycero-3-phosphoethanolamine (TRITC-DHPE) were obtained from Invitrogen. The calcium indicator Fluo-8H (sodium salt; ABD Bioquest) was used for all experiments imaging the ionic flux through EqtlI pores.


### Purification, labeling, and characterization of EqtlI

An A179C mutant of EqtlI was expressed recombinantly in *Escherichia coli* BL21 (DE3). This C-terminal mutation has been shown to be amenable to modifications without affecting permeabilizing activity (28). The C-terminus is distant from parts of the molecule that participate in membrane binding (11,12,29) or formation of the final transmembrane pore (14,30) and are likely to be fully exposed to the solvent in both the membrane-bound and pore form of the protein (28,31). EqtlI A179C was purified as described previously (32) in the presence of 2 mM dithiothreitol (DTT) to prevent oxidation of the thiol group. After chromatography, the protein was concentrated by ultrafiltration and washed thoroughly with degassed buffer (20 mM phosphate, pH 7.2) to remove the DTT before labeling with Cy3B maleimide (GE Healthcare). Cy3B maleimide (5 mg mL<sup>-1</sup> in dimethyl sulfoxide) was mixed with the A179C solution to a final molar dye/protein ratio of 4:1. The reaction mixture was incubated in the dark at ambient temperature for 2 h. Labeled A179C (EqtlI-Cy3B) was separated from the unreacted dye by fast protein liquid chromatography (HiPrep ion exchange; GE Healthcare). Finally, EqtlI-Cy3B was concentrated using a Centricon ultrafiltration membrane (3 kDa MWCO; Millipore) to a final concentration of 75  $\mu\text{M}$ . Efficiency of labeling was measured from the absorbance spectrum with a dye/protein ratio of  $1.01 \pm 0.02$ . Labeling was also confirmed by SDS-PAGE gel scanned under UV light before Coomassie staining (Fig. S1 A in the Supporting Material).

EqtlI-Cy3B activity was assessed via hemolysis of bovine red blood cells as described previously (29). The bovine red blood cells were washed three times with erythrocyte buffer (130 mM NaCl, 20 mM Tris-HCl, pH 7.4). Serial twofold dilutions of the protein were made in microtiter plate into a final volume of 100  $\mu\text{L}$  of erythrocyte buffer. The same volume of erythrocyte suspension in erythrocyte buffer ( $A_{630} = 0.5$ ) was added to each well and hemolysis was monitored as a decrease in absorption at 630 nm for 20 min at room temperature. The hemolytic activity of the EqtlI A179C mutant and Cy3B-labeled mutant (EqtlI-Cy3B) was indistinguishable from that of the wild-type protein (Fig. S1 B).

### DIBs

DIBs were prepared as described previously (24,25) (Fig. 1). Briefly, 140  $\mu\text{L}$  of molten 0.75% (w:v) low-melting-point agarose was deposited



**FIGURE 1** Schematic. A Droplet Interface Bilayer is formed between an agarose-coated microscope coverslip and an aqueous droplet in a solution of lipids in hexadecane. (A) Monolayers form at droplet/agarose interfaces in a microfabricated device. (B) Piezo-driven nanoinjection from a glass pipette is used to deliver EqtlI-Cy3B to the droplet. (C) Insertion of an agarose-coated microelectrode into the droplet permits control of the applied potential, and measurement of gigaohm seal single-channel currents. TIRF microscopy of the bilayer is possible through the coverslip. To see this figure in color, go online.

on a plasma-cleaned coverslip by spin coating (30 s at 4000 rpm). A microchannel device was fabricated from polymethyl methacrylate (PMMA) (24). The purpose of this device was twofold: 1), to provide multiple wells to contain the oil-lipid solution on top of the agarose-coated coverslip; and 2), to maintain the hydration of the substrate-agarose through contact of the substrate with a network of agarose-filled channels. The microchannel device was placed on top of the coverslip and filled with rehydrating agarose (1.5 M KCl, 10 mM HEPES, pH 7). Lipid solutions were prepared by drying a film of lipid from chloroform before adding hexadecane. Lipids dissolved in hexadecane were pipetted into the device wells. Solutions of Chol in hexadecane were either pipetted into the wells before bilayer formation or added to the wells after the bilayer was already formed, as indicated in the respective results. Then 50 nL droplets (1.5 M KCl, 10 mM HEPES, pH 7) were prepared in the hexadecane lipid mixture and pipetted into the microchannel device after 15 min. A lipid bilayer spontaneously formed at the interface between the agarose substrate and the aqueous droplet. For calcium flux imaging, 750 mM CaCl<sub>2</sub> was added to the rehydrating agarose solution, and droplets contained 50 μM Fluo-8H and 370 μM EDTA in addition to 1.5 M KCl, 10 mM HEPES, at pH 7.

### Droplet nanoinjection

Borosilicate capillaries were pulled to an ~10 μm inner diameter and back-filled with hexadecane before they were attached to a piezo-driven injector (Nanoliter 2000; World Precision Instruments). Protein solution was loaded into the capillary (typically 200 nL) by piston displacement causing suction. The injector was manipulated into position through the use of a three-dimensional micromanipulator (Narishige, Japan). A set volume of protein solution (usually 4.6 nL) was then introduced into a droplet by bringing the capillary tip into contact with the droplet and ejecting the solution into the droplet as described previously (26).

### Fluorescence imaging

We measured fluorescence using an inverted microscope (Ti-E; Nikon). We used 532 nm (Compass 215M; Coherent) and 473 nm (Shanghai Dream Lasers Technology) laser excitation to image Cy3B and DiOC<sub>18</sub> (2) fluorescence, respectively. The excitation light was focused at the back aperture of an oil immersion objective lens (60 × Plan Apo N.A. 1.4; Nikon) so that it was totally internally reflected at the coverslip surface. Emitted fluorescence was collected through the same objective, transmitted through suitable dichroic and emission filters (HQ595/50M and HHQ550LP (Chroma) for Cy3B emission, and 525/30 (Semrock) for Fluo8H and DiOC<sub>18</sub> (2) emission). Images were recorded with the use of electron-multiplying CCDs (iXon+ DV860E or iXon3 DU860; Andor Technology). Temperature was controlled with a heated microscope stage (PE100; Linkam Scientific Instruments).

### Pore diffusion

We determined the location of individual EqII pores by tracking the position of fluorescent spots corresponding to Ca<sup>2+</sup> ion flux through each pore. For spots that moved during an image sequence, we used the Trackmate (33) algorithm compiled for ImageJ (34) (<http://fiji.sc/TrackMate>) to track all pores present on the bilayer. Individual mean-squared displacements versus time lag were computed for each pore, and the gradient of each plot (4D<sub>lat</sub>(t)) was used to generate a distribution of diffusion coefficients (Fig. 2 D).

### Electrical measurements

An Ag/AgCl electrode in the droplet and an equivalent ground electrode in the agarose enabled electrical measurements and control of transmembrane

potential. Currents were recorded with a patch-clamp amplifier (Axopatch 200B; Axon Instruments) and Windows Electrophysiology Disk Recorder software (WinEDR, John Dempster Strathclyde Institute of Pharmacy and Biomedical Science). A postacquisition 1 kHz low-pass filter was applied. The microchannel device, electrodes, and patch-clamp head stage were all enclosed in a purpose-built Faraday cage attached to the inverted microscope.

## RESULTS

We measured ionic flux through Cy3B-EqtII pores from the localized fluorescence caused by Fluo8H binding to calcium ions as they passed from the substrate agarose through the pore into the droplet. We also measured the time-dependent changes in the distribution of EqtII-Cy3B within DIBs exhibiting liquid-disordered (L<sub>d</sub>) and liquid-ordered (L<sub>o</sub>) phase coexistence.

### EqtII forms pores in the L<sub>d</sub> phase

We observed pore formation and diffusion using the Ca<sup>2+</sup> indicator dye Fluo-8H in the droplet to obtain an optical measurement of ionic flux (35). Under an applied potential difference across the bilayer (−60 mV), calcium ions present in the agarose layer (750 mM) pass through the pore and into the droplet. Chelation of this calcium by Fluo-8H (50 μM) gives rise to a localized fluorescent spot at the location of the pore. The bilayer was illuminated with 473 nm laser light, and the Fluo-8H emission fluorescence due to the calcium flux was imaged at the camera.

DIBs were formed with a lipid composition that exhibited L<sub>o</sub>/L<sub>d</sub> phase coexistence (4:3:3 DPhPC/eSM/Chol). Using a piezo-driven glass micropipette, we injected 4.6 nL of 10 μM Cy3B-labeled EqtII into the droplet. Cy3B emission was used to determine EqtII location. Pore formation was subsequently observed as the appearance of diffusing spots corresponding to calcium flux across the bilayer (Fig. 2, A and B).

Simultaneous single-channel electrical recording and fluorescence imaging on bilayers at lower EqtII concentration (100 nM) using a bilayer without the complication of phase coexistence (DPhPC:SM 9:1) enabled us to confirm that Fluo-8H spot appearance correlated directly with ionic current through a single EqtII pore (Fig. 2 C).

The bilayer area corresponding to EqtII binding coincided with regions labeled with the L<sub>d</sub> marker DiOC<sub>18</sub> (2) (Fig. 3 A). Other fluorescent markers of the L<sub>d</sub> phase (19,36,37) (DiI and TRITC-DHPE) supported this assignment (Figs. S2 and S4). Lipid mixtures corresponding to the expected two-phase and single-phase regions of the phase diagram also supported this assignment (Fig. S3).

We quantified the preferential location of EqtII pores present in Fig. 2 A by first tracking the location of the pores and then comparing the pore locations with a binary image of EqtII-Cy3B fluorescence. We generated the binary image by applying a threshold to the EqtII-Cy3B image at the





FIGURE 2 EqtlI-Cy3B pores diffuse and form in the  $L_d$  phase. (A) EqtlI-Cy3B pores were visualized by the  $\text{Ca}^{2+}$  flux using Fluo-8H fluorescence in a DPhPC/eSM/Chol 4:3:3 DIB. The edge of the DIB is visible as an arc in the upper-right quadrant of the images. Pores form in the  $L_d$  phase. Scale bar:  $10 \mu\text{m}$ . Also see [Movie S1](#). (B) Image sequence from a  $10 \times 10 \mu\text{m}$  region of A, 100 ms per image, running left to right, showing pore appearance in the  $L_d$  phase. (C) Simultaneous measurement of Fluo8H  $\text{Ca}^{2+}$  flux (top trace) and electrical current (bottom trace) from a single EqtlI-Cy3B pore. Inset images show the pore at specific time points; scale bar:  $5 \mu\text{m}$ . Applied potential  $-60 \text{ mV}$ . (D) Pore diffusion from the data set in A was Brownian and fit to a  $\gamma$  distribution of diffusion coefficients ( $n = 3287$ ). (E) The distribution of pore intensities from the data in A shows distinct peaks. Data were fit to the sum of three log-normal distributions. (F) The rate of pore appearance over the timescale of our experiment was constant. To see this figure in color, go online.

intensity corresponding to a minimum population in the histogram of pixel intensities (i.e., between the histogram peaks corresponding to dark and light areas). We assigned 95% ( $n = 3287$ ) of pore locations to the  $L_d$  phase. For those pores assigned to the  $L_o$  phase, manual inspection of the original image showed failure of image thresholding to assign small low-contrast features to the correct phase. Pore formation initiated only from within the  $L_d$  phase, and not from the phase boundary or the  $L_o$  phase (Fig. 2, A and B; [Movie S1](#)).

We also examined the diffusive behavior of pores. Within a single experiment, pore diffusion was Brownian, and the distribution of diffusion coefficients (Fig. 2 D) could be fit with a single  $\gamma$  distribution ( $\theta = 0.78 \pm 0.03$ ,  $\mu = 2.4 \pm 0.1 \mu\text{m}^2 \text{s}^{-1}$ ). In interpreting this result, we must caution that between different experiments on different bilayers, although diffusion was always Brownian and always described by a single-component distribution, we observed significant variation in the mean diffusion coefficient. We believe these changes correspond to variation in the



**FIGURE 3** EqtII-Cy3B preferentially localizes to the domain boundary before being found in the L<sub>d</sub> phase. **(A)** First row: A DPhPC/eSM/Chol 4:1:1 bilayer containing 0.1% DiOC<sub>18</sub>(2) as a marker for L<sub>d</sub> phase was formed. Second row: EqtII-Cy3B (1 μM) was injected into the droplet to a final concentration of ~100 nM. **(B)** Image sequence showing time-dependent accumulation of EqtII fluorescence at the domain boundary. Scale bar: 10 μm. **(C)** Line profile across the images in **B**. A relative offset of 2000 a.u. between each trace has been applied for clarity. **(D)** Time dependence of fluorescence from the images in **B** taken from three regions of interest (ROIs): inside the central domain (green solid line), at the domain boundary (blue dotted line), and outside the central domain (red dashed line). ROIs are shown in Fig. S5. Error bars represent the SD in pixel intensity for the ROIs. To see this figure in color, go online.

hydration of the underlying agarose support, as dehydration of the agarose over a period of 24 h resulted in all pores becoming immobile.

The distribution of pore intensities revealed several distinct peaks corresponding to different pore conductances (Fig. 2 E). We observed similar peaks in optical ionic flux for pore formation in the antimicrobial peptide Alamethicin (38). Because these intensity changes are apparent in individual diffusing pores (Fig. 2 C), the most likely explanation is that different-sized EqtII pores are present, although we cannot formally exclude the possibility that multiple pores diffuse in a single diffraction-limited cluster. An assignment

of multiple conductance states is consistent with the multiple conductances reported for planar lipid bilayer recordings of EqtII (15). Pore intensity scales linearly with pore current for our applied potential (−60 mV) (Fig. S6).

Once formed, pores persisted throughout the lifetime of our observations (minutes). We did not observe pore closure. Pores appeared at a uniform rate during our measurements (Fig. 2 F). Although we did not attempt to quantify the dependence of pore formation on EqtII, the surface density of the pores did qualitatively increase with the concentration of EqtII-Cy3B added to the droplet. Averaged over all our experiments, the mean bilayer area per pore

was  $621 \mu\text{m}^2$  at 100 mM EqtII, whereas at  $1 \mu\text{M}$  EqtII, the mean bilayer area per pore decreased to  $52 \mu\text{m}^2$ .

### EqtII concentration is first enhanced at the phase boundary and then in the $L_d$ phase

To study more closely the effects of EqtII-Cy3B on bilayers containing two phases, we formed bilayers using a DPhPC/eSM/Chol lipid mixture at a 4:1:1 molar ratio. Subsequently, EqtII-Cy3B (4.6 nL,  $1 \mu\text{M}$ ) was injected into the droplet to a final concentration of  $\sim 100$  nM, and its localization on the bilayer was observed. At early times, EqtII-Cy3B appeared concentrated at the domain boundaries (Fig. 3 A; Movie S2). Note that, similarly to previous measurements on lipid monolayers (18), the distribution of EqtII-Cy3 fluorescence in the  $L_o$  phase appeared uneven. This phenomena was also time dependent, and at early times there was an even and equal distribution of fluorescence in both phases (Movie S2).

Over time, EqtII-Cy3B was found in the same areas as the DiOC<sub>18</sub> (2) dye, i.e., the  $L_d$  phase (Fig. 3 B). Although transmembrane peptides in general partition into  $L_d$  phases in model membranes (39), this result was unexpected because EqtII was previously observed to bind preferentially to the  $L_o$  phase (19). The proportion of bilayer area in each phase was also affected by the binding of EqtII to the lipid bilayer:  $L_d$  domains shrank and  $L_o$  domains increased in size (Fig. 3).

We examined the time dependence of fluorescence intensity. At early times, EqtII-Cy3B was enriched at the phase boundary between the domains (Fig. 3). This is in agreement with previous non-time-dependent observations (18,19). However, after this initial period of enhanced concentration at the phase boundary, we observed that EqtII subsequently increased in concentration in the  $L_d$  phase, where protein preferentially accumulates (Fig. 3).

## DISCUSSION

We observed that EqtII-Cy3B bound preferentially to the interface between different lipid phases before being found predominantly in the  $L_d$  phase (Fig. 3). With the time resolution of our experiments, we did not detect any lag between EqtII binding to  $L_o$  and  $L_d$  phases, and binding at the  $L_o/L_d$  domain boundaries. Our results are consistent with a model in which EqtII binding is SM dependent (10), causing a preferential binding at domain boundaries where imperfect lipid packing is present and SM headgroups may be more exposed. Another potential cause of this preferential binding would be simple saturation of favorable binding sites at the domain boundaries, before accumulation of EqtII from solution to the  $L_d$  phase. However, given the apparently equal distribution of EqtII in  $L_d$  and  $L_o$  phases at early times (Fig. 3 B; Movie S2), followed by an increase of fluorescence in the  $L_d$  phase at longer times (Fig. 3 D), we do not favor this interpretation.

After initial binding at the interface, labeled EqtII was found preferentially in the  $L_d$  domains (Fig. 3). This result was somewhat unexpected because, although EqtII was previously observed to bind at the lipid interface, it was found to locate preferentially to the  $L_o$  phase in GUVs composed of a mixture of 1,2-dioleoyl-*sn*-glycero-3-phosphocholine, stearyl-SM, and Chol (19). Given these conflicting results, we cautiously confirmed localization of EqtII to the  $L_d$  phase in our lipid system, both by using different fluorescent probes that partition preferentially to the disordered phase (Figs. 3, S2, and S4) and by observing compositions expected to correspond to single- or two-phase regions of the phase diagram (Fig. S3). In agreement with our study, Barlič et al. (18) observed a similar distribution of EqtII in lipid monolayers composed of egg-PC, eSM, and Chol, where EqtII preferentially localized to domain interfaces and the  $L_d$  phase.

After localization of EqtII in the  $L_d$  phase, we observed subsequent pore formation within the  $L_d$  phase by calcium flux imaging and current measurements (Fig. 2, A–C). It has been suggested that protein binding at domain boundaries aids pore formation by increasing the local concentration of toxin monomers (18,19). Here, however, we did not observe pore formation at boundaries, but only within the  $L_d$  phase (Movie S2). Pores in the  $L_d$  phase were not observed to diffuse into the ordered phase. Pore formation was a relatively rare event, with a significant concentration of non-pore-forming EqtII present in the  $L_d$  phase. In agreement with previous work on large unilamellar vesicles (15,40), our data confirm the presence of a large protein pool in the  $L_d$  domains, in which pore formation occurs. These observations are also in agreement with a study by Poklar et al. (41), in which no EqtII insertion was observed in ordered bilayers. GUVs that were composed of SM/Chol (1:1 ratio) and in  $L_o$  phase were also not susceptible to pore formation, even though EqtII did bind to them (19).

Given the results of these experiments, we suggest two potential models of EqtII action: 1), preferential binding at  $L_o/L_d$  domain boundaries followed by helix insertion, diffusion of EqtII into the  $L_d$  phase, and then pore formation; and 2), binding at domain boundaries followed by saturation of these binding sites, leading to dominant binding occurring from solution to the  $L_d$  phase, and then subsequent insertion and pore formation from the  $L_d$  phase.

How might our observations be related to the *in vivo* action of EqtII? To some extent, EqtII colocalizes in cells with markers for lipid rafts (20), and homologous sticholysin II localizes to detergent-resistant membranes (42). These results might be reconciled if EqtII preferentially binds to the domain boundaries rather than to the  $L_o$  domains, or if the  $L_o/L_d$  phase coexistence observed in this work is different from that observed *in vivo*. Clearly, the situation in cells is more complex, as was shown recently in a comparative study that employed EqtII and another SM-specific pore-forming toxin, lysenin, and found three

different pools of SM that were stained by either EqII or lysenin, or both (43).

Segregation at domain boundaries has been reported in a number of systems, including simulations of lipid-packing-driven  $\alpha$ -helix segregation (39) and domain formation (44), simulations of lipoproteins (45), and clustering at domain boundaries in nonlipid amphiphiles (46). For example, a combination of two-photon fluorescence microscopy and atomic force microscopy imaging of N-Ras showed preferential binding to  $L_d$  domains and at  $L_o/L_d$  domain boundaries, similar to what we observed here for EqII (47). Domain boundaries clearly have a dramatic effect on the mechanism of EqII pore formation, and these effects have been predicted more generally to play a key role in the preferential adsorption and accumulation of membrane-spanning peptides (39). This domain-dependent mechanism might also be generalized for other pore-forming toxins. For example, the lipid-phase distribution of  $\beta$ -barrel pore-forming toxins appears to depend on hydrophobic mismatch between the bilayer thickness and the protein transmembrane segment, as was recently shown for the pore-forming toxin perfringolysin O (48).

## SUPPORTING MATERIAL

Six figures and two movies are available at [http://www.biophysj.org/biophysj/supplemental/S0006-3495\(14\)00223-9](http://www.biophysj.org/biophysj/supplemental/S0006-3495(14)00223-9).

N.R. and G.A. received support from the Slovenian Research Agency and Ad Futura, Slovene Human Resources Development and Scholarship Fund. M.I.W. is funded by the ERC and the BBSRC. B.C. is an EPSRC LSI postdoctoral fellow, and J.S.H.D. is a Weidenfeld scholar.

## REFERENCES

- Parker, M. W., and S. C. Feil. 2005. Pore-forming protein toxins: from structure to function. *Prog. Biophys. Mol. Biol.* 88:91–142.
- Anderluh, G., and J. H. Lakey. 2008. Disparate proteins use similar architectures to damage membranes. *Trends Biochem. Sci.* 33:482–490.
- Voskoboinik, I., M. J. Smyth, and J. A. Trapani. 2006. Perforin-mediated target-cell death and immune homeostasis. *Nat. Rev. Immunol.* 6:940–952.
- Gilbert, R., M. Mikelj, M. Dalla Serra, C. Froelich, and G. Anderluh. 2013. Effects of MACPF/CDC proteins on lipid membranes. *Cell. Mol. Life Sci.* 70:2083–2098.
- Gonzalez, M. R., M. Bischofberger, ..., F. G. van der Goot. 2011. Pore-forming toxins induce multiple cellular responses promoting survival. *Cell. Microbiol.* 13:1026–1043.
- Anderluh, G., and P. Maček. 2002. Cytolytic peptide and protein toxins from sea anemones (Anthozoa: Actiniaria). *Toxicon.* 40:111–124.
- Kristan, K. C., G. Viero, ..., G. Anderluh. 2009. Molecular mechanism of pore formation by actinoporins. *Toxicon.* 54:1125–1134.
- García-Ortega, L., J. Alegre-Cebollada, ..., J. G. Gavilanes. 2011. The behavior of sea anemone actinoporins at the water-membrane interface. *Biochim. Biophys. Acta.* 1808:2275–2288.
- Maček, P. 1992. Polypeptide cytolytic toxins from sea anemones (Actiniaria). *FEMS Microbiol. Immunol.* 5:121–129.
- Bakrač, B., I. Gutiérrez-Aguirre, ..., G. Anderluh. 2008. Molecular determinants of sphingomyelin specificity of a eukaryotic pore-forming toxin. *J. Biol. Chem.* 283:18665–18677.
- Bakrač, B., A. Kladnik, ..., G. Anderluh. 2010. A toxin-based probe reveals cytoplasmic exposure of Golgi sphingomyelin. *J. Biol. Chem.* 285:22186–22195.
- Hong, Q., I. Gutierrez-Aguirre, ..., G. Anderluh. 2002. Two-step membrane binding by Equinatoxin II, a pore-forming toxin from the sea anemone, involves an exposed aromatic cluster and a flexible helix. *J. Biol. Chem.* 277:41916–41924.
- Mancheño, J. M., J. Martín-Benito, ..., J. A. Hermoso. 2003. Crystal and electron microscopy structures of sticholysin II actinoporin reveal insights into the mechanism of membrane pore formation. *Structure.* 11:1319–1328.
- Kristan, K., Z. Podlesek, ..., G. Anderluh. 2004. Pore formation by equinatoxin, a eukaryotic pore-forming toxin, requires a flexible N-terminal region and a stable  $\beta$ -sandwich. *J. Biol. Chem.* 279:46509–46517.
- Belmonte, G., C. Pederzoli, ..., G. Menestrina. 1993. Pore formation by the sea anemone cytolyisin equinatoxin II in red blood cells and model lipid membranes. *J. Membr. Biol.* 131:11–22.
- Anderluh, G., M. Dalla Serra, ..., G. Menestrina. 2003. Pore formation by equinatoxin II, a eukaryotic protein toxin, occurs by induction of nonlamellar lipid structures. *J. Biol. Chem.* 278:45216–45223.
- Mechaly, A. E., A. Bellomio, ..., D. M. Guérin. 2011. Structural insights into the oligomerization and architecture of eukaryotic membrane pore-forming toxins. *Structure.* 19:181–191.
- Barlič, A., I. Gutiérrez-Aguirre, ..., J. M. González-Mañas. 2004. Lipid phase coexistence favors membrane insertion of equinatoxin-II, a pore-forming toxin from *Actinia equina*. *J. Biol. Chem.* 279:34209–34216.
- Schön, P., A. J. García-Sáez, ..., P. Schwille. 2008. Equinatoxin II permeabilizing activity depends on the presence of sphingomyelin and lipid phase coexistence. *Biophys. J.* 95:691–698.
- García-Sáez, A. J., S. B. Buschhorn, ..., P. Schwille. 2011. Oligomerization and pore formation by equinatoxin II inhibit endocytosis and lead to plasma membrane reorganization. *J. Biol. Chem.* 286:37768–37777.
- Bakrač, B., and G. Anderluh. 2010. Molecular mechanism of sphingomyelin-specific membrane binding and pore formation by actinoporins. *Adv. Exp. Med. Biol.* 677:106–115.
- Anderluh, G., A. Razpotnik, ..., R. S. Norton. 2005. Interaction of the eukaryotic pore-forming cytolyisin equinatoxin II with model membranes: 19F NMR studies. *J. Mol. Biol.* 347:27–39.
- Bayley, H., B. Cronin, ..., M. Wallace. 2008. Droplet interface bilayers. *Mol. Biosyst.* 4:1191–1208.
- Leptihn, S., O. K. Castell, ..., M. I. Wallace. 2013. Constructing droplet interface bilayers from the contact of aqueous droplets in oil. *Nat. Protoc.* 8:1048–1057.
- Heron, A. J., J. R. Thompson, ..., M. I. Wallace. 2009. Simultaneous measurement of ionic current and fluorescence from single protein pores. *J. Am. Chem. Soc.* 131:1652–1653.
- Thompson, J. R., B. Cronin, ..., M. I. Wallace. 2011. Rapid assembly of a multimeric membrane protein pore. *Biophys. J.* 101:2679–2683.
- Sezgin, E., I. Levental, ..., P. Schwille. 2012. Partitioning, diffusion, and ligand binding of raft lipid analogs in model and cellular plasma membranes. *Biochim. Biophys. Acta.* 1818:1777–1784.
- Anderluh, G., A. Barlič, ..., P. Macek. 1998. Avidin-FITC topological studies with three cysteine mutants of equinatoxin II, a sea anemone pore-forming protein. *Biochem. Biophys. Res. Commun.* 242:187–190.
- Malovrh, P., A. Barlič, ..., G. Anderluh. 2000. Structure-function studies of tryptophan mutants of equinatoxin II, a sea anemone pore-forming protein. *Biochem. J.* 346:223–232.
- Malovrh, P., G. Viero, ..., G. Anderluh. 2003. A novel mechanism of pore formation: membrane penetration by the N-terminal amphipathic region of equinatoxin. *J. Biol. Chem.* 278:22678–22685.

31. Anderluh, G., A. Barlič, ..., G. Menestrina. 1999. Cysteine-scanning mutagenesis of an eukaryotic pore-forming toxin from sea anemone: topology in lipid membranes. *Eur. J. Biochem.* 263:128–136.
32. Anderluh, G., J. Pungercar, ..., F. Gubenšek. 1996. Cloning, sequencing, and expression of equinatoxin II. *Biochem. Biophys. Res. Commun.* 220:437–442.
33. Jaqaman, K., D. Loerke, ..., G. Danuser. 2008. Robust single-particle tracking in live-cell time-lapse sequences. *Nat. Methods.* 5:695–702.
34. Schneider, C. A., W. S. Rasband, and K. W. Eliceiri. 2012. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods.* 9:671–675.
35. Shuai, J., and I. Parker. 2005. Optical single-channel recording by imaging  $\text{Ca}^{2+}$  flux through individual ion channels: theoretical considerations and limits to resolution. *Cell Calcium.* 37:283–299.
36. Baumgart, T., G. Hunt, ..., G. W. Feigenson. 2007. Fluorescence probe partitioning between Lo/Ld phases in lipid membranes. *Biochim. Biophys. Acta.* 1768:2182–2194.
37. Stachowiak, J. C., C. C. Hayden, ..., D. Y. Sasaki. 2011. Targeting proteins to liquid-ordered domains in lipid membranes. *Langmuir.* 27:1457–1462.
38. Harriss, L. M., B. Cronin, ..., M. I. Wallace. 2011. Imaging multiple conductance states in an alamethicin pore. *J. Am. Chem. Soc.* 133:14507–14509.
39. Schäfer, L. V., D. H. de Jong, ..., S. J. Marrink. 2011. Lipid packing drives the segregation of transmembrane helices into disordered lipid domains in model membranes. *Proc. Natl. Acad. Sci. USA.* 108:1343–1348.
40. Tejuca, M., M. D. Serra, ..., G. Menestrina. 1996. Mechanism of membrane permeabilization by sticholysin I, a cytolyisin isolated from the venom of the sea anemone *Stichodactyla helianthus*. *Biochemistry.* 35:14947–14957.
41. Poklar, N., J. Fritz, ..., T. V. Chalikian. 1999. Interaction of the pore-forming protein equinatoxin II with model lipid membranes: a calorimetric and spectroscopic study. *Biochemistry.* 38:14999–15008.
42. Alegre-Cebollada, J., I. Rodríguez-Crespo, ..., A. M. del Pozo. 2006. Detergent-resistant membranes are platforms for actinoporin pore-forming activity on intact cells. *FEBS J.* 273:863–871.
43. Yachi, R., Y. Uchida, ..., H. Arai. 2012. Subcellular localization of sphingomyelin revealed by two toxin-based probes in mammalian cells. *Genes Cells.* 17:720–727.
44. Domański, J., S. J. Marrink, and L. V. Schäfer. 2012. Transmembrane helices can induce domain formation in crowded model membranes. *Biochim. Biophys. Acta.* 1818:984–994.
45. Janosi, L., Z. Li, ..., A. A. Gorfe. 2012. Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. *Proc. Natl. Acad. Sci. USA.* 109:8097–8102.
46. Muddana, H. S., H. H. Chiang, and P. J. Butler. 2012. Tuning membrane phase separation using nonlipid amphiphiles. *Biophys. J.* 102:489–497.
47. Nicolini, C., J. Baranski, ..., R. Winter. 2006. Visualizing association of N-ras in lipid microdomains: influence of domain structure and interfacial adsorption. *J. Am. Chem. Soc.* 128:192–201.
48. Lin, Q., and E. London. 2013. Altering hydrophobic sequence lengths shows that hydrophobic mismatch controls affinity for ordered lipid domains (rafts) in the multitransmembrane strand protein perfringolysin O. *J. Biol. Chem.* 288:1340–1352.



## **Lipid phase dependence of Equinatoxin II membrane binding and pore formation**

N. Rojko<sup>1</sup>, B. Cronin<sup>2</sup>, J. S. H. Danial<sup>2</sup>, M. A. B. Baker<sup>2</sup>, G. Anderluh<sup>1,3</sup>, M. I. Wallace<sup>2</sup>.

<sup>1</sup> Department of Biology, Biotechnical faculty, University of Ljubljana, Večna pot, 111, 1000 Ljubljana, Slovenia.

<sup>2</sup> Department of Chemistry, Oxford University, 12 Mansfield Rd, Oxford, OX1 3TA, UK.

<sup>3</sup> National Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia.

*Corresponding authors:* [mark.wallace@chem.ox.ac.uk](mailto:mark.wallace@chem.ox.ac.uk)/[gregor.anderluh@ki.si](mailto:gregor.anderluh@ki.si)


### **Supplementary Movie S1**

EqII-Cy3B (red) pores diffuse in the L<sub>d</sub> phase on a DPhPC:eSM:Chol 4:3:3 bilayer. (a) Functional EqII-Cy3B pores were visualized by the Ca<sup>2+</sup> flux through the pore using Fluo-8H fluorescence (green). 17.5 x 17.5 μm image. 100 ms per image acquisition. Playback at 40 ms per image.

### **Supplementary Movie S2**

At low EqII-Cy3B concentrations (~50 nM) individual molecules can be resolved. 1D diffusion of EqII-Cy3B at the domain boundaries is evident, as is the presence of EqII-Cy3B in both phases. Scale bar 10 μm. Images were recorded at 100 ms. Playback at 40 ms per image.

**Figure S1**



**FIGURE S1: Properties of EqtII A179C-Cy3B.** (A) SDS-PAGE of purified labelled protein (left) and the same gel under UV light prior staining of the gel with Coomassie blue. M, Marker lane; 1, EqtII; 2, EqtII A179C-Cy3B. (B) Hemolytic activity measured using the lysis of bovine red blood cells.

**Figure S2**




FIGURE S2: Image of a DPhPC:SM:Chol 1:2:2 bilayer containing 0.0001% DiI as a marker for the  $L_d$  phase. (a) DiI fluorescence prior to EqtII injection. Contrast is low in this image, in comparison to panels b and c, as reduced laser power is used to limit premature photobleaching. The bright spots are likely due to oil inclusions below the bilayer in which DiI is highly soluble. (b) EqtII-Cy3b (final concentration approximately 700 nM) was injected into the droplet and image was recorded 90 s after injection. (c) 5 min after injection the addition of the toxin has resulted in a reordering of the lipid in the bilayer. (d) Contrast-enhanced duplicate of (a). Scale bar indicates 10  $\mu\text{m}$ .

**Figure S3**




FIGURE S3: Three DPhPC:SM:Chol compositions, expected to correspond to two-phase and single-phase regions of the phase diagram. We are not aware of any published phase diagram for the specific combination of DPhPC:SM:Chol. However in broad terms, phase diagrams for all ternary lipid mixtures of cholesterol with two lipids with different melting temperatures show similarity (1–3). (A) Modified phase diagram from Dimova and co-workers for DOPC:eSM:Chol (4). This is for a different lipid mixture to that used here, but can be used as rough guide to where we might expect phase boundaries to lie. Numbering on this diagram indicates lipid compositions for DPhPC:eSM:Chol chosen to probe the phase diagram (1) 1:1:1, (2) 2:1:1, and (3) 8:1:1. (B) Images of droplet bilayers corresponding to the lipid compositions referred to in (A). Scale bar 10  $\mu\text{m}$ .

Figure S4




FIGURE S4: Image sequence following heating of a DIB formed from a 1:1:1 DPhPC:SM:Chol mixture with 0.5% *N*-(6-tetramethylrhodaminethiocarbamoyl)-1,2-dihexadecanoyl-*sn*-glycero-3-phosphoethanolamine (TRITC-DHPE) used as marker for the  $L_d$  phase (5). Heating from 22 (top left) to 30°C (bottom right) over a period of 5 minutes results in shrinkage of the area fraction of the putative  $L_o$  phase. Scale bar 10  $\mu\text{m}$ .

**Figure S5**




FIGURE S5: Image from Fig 3B depicting the regions of interest used to compute the time-dependent changes in fluorescence intensity seen in Fig. 3D. As per the colour coding of Fig. 3D, red is outside the domain, blue is at the domain boundary, and green is inside the domain boundary.

**Figure S6**




FIGURE S6: (B) Fluorescence-current plot of the data in Fig. 2C is linear.

### **Supplementary References**

1. Feigenson, G.W. 2006. Phase behavior of lipid mixtures. *Nat. Chem. Biol.* 2: 560–563.
2. Feigenson, G.W. 2009. Phase diagrams and lipid domains in multicomponent lipid bilayer mixtures. *Biochim. Biophys. Acta.* 1788: 47–52.
3. Petruzielo, R.S., F.A. Heberle, P. Drazba, J. Katsaras, and G.W. Feigenson. 2013. Phase behavior and domain size in sphingomyelin-containing lipid bilayers. *Biochim. Biophys. Acta Bba - Biomembr.* 1828: 1302–1313.

4. Bezlyepkina, N., R.S. Gracià, P. Shchelokovskyy, R. Lipowsky, and R. Dimova. 2013. Phase Diagram and Tie-Line Determination for the Ternary Mixture DOPC/eSM/Cholesterol. *Biophys. J.* 104: 1456–1464.
5. Stachowiak, J.C., C.C. Hayden, M.A.A. Sanchez, J. Wang, B.C. Bunker, et al. 2011. Targeting Proteins to Liquid-Ordered Domains in Lipid Membranes. *Langmuir.* 27: 1457–1462.